Compare LFMD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFMD | CTNM |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.5M | 328.1M |
| IPO Year | N/A | 2024 |
| Metric | LFMD | CTNM |
|---|---|---|
| Price | $3.50 | $11.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $10.22 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.7M | 169.9K |
| Earning Date | 11-17-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $250,091,814.00 | N/A |
| Revenue This Year | $13.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $3.43 | $3.35 |
| 52 Week High | $15.84 | $15.25 |
| Indicator | LFMD | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 24.69 | 49.67 |
| Support Level | $3.43 | $10.42 |
| Resistance Level | $3.84 | $11.43 |
| Average True Range (ATR) | 0.28 | 0.80 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 5.18 | 28.10 |
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.